spacer
home > epc > autumn 2008 > electric avenue
PUBLICATIONS
European Pharmaceutical Contractor

Electric Avenue

THE BENEFITS OF ELECTRONIC DATA CAPTURE

The promise of information technology is being realised by businesses around the world. This is evidenced is in the way computing power allows tasks, and even entire processes, to be completed whilst providing the additional benefits of improved methodologies, higher speeds and lower costs. Now, stakeholders of electronic data capture (EDC) are looking to achieve similar benefits in their clinical trial processes earlier on, prior to deploying a finished solution. Some believe the answer lies in a more effective way of implementing EDC. They contend that the days of expensive technology transfer, long implementation times and resource-intensive processes are coming to an end.

As the pharmaceutical industry moves higher up the learning and experience curves for EDC, there is less debate about the need for, and benefits of, EDC solutions as a powerful and necessary component in the clinical trial landscape. The discussion has moved beyond the question of whether EDC is useful, because these web-based systems are allowing investigators to log their findings directly into a centralised database, delivering accurate data in near real-time. These data may then be analysed for such purposes as reviewing the progress of clinical trials, supporting trial adaptation and reducing the costs of providing statisticians with study information. EDC also helps improve efficiencies – a benefit of great interest in drug development.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simon Hawken has more than 20 years’ experience of selling solutions into the biopharmaceutical sector. He currently serves as Director of Business Development for eResearchTechnology, Inc – the well-established cardiac safety leader also providing eClinical solutions – and is based in the UK. He holds a BA degree in Economics and has worked for IMS Health, IBM Corporation, Xerox and BEA Systems Inc, among others.
spacer
Simon Hawken
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement